Polymers for viral gene delivery

Bibliography

• Koostra NA, Verma IM. Gene therapy with viral vectors. Ann Rev Pharmacol Toxicol 2003;43:413-39
   PubMed Web of Science ®Google Scholar
• Chong H, Starkey W, Vile RG. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J Virol 1998;72:2663-70
   PubMed Web of Science ®Google Scholar
• Marzio G, Kerkvlict E, Bogaards JA, et al. A replication-competent adenovirus assay for E1-detected Ad35 vectors produced in PER.C6 cells. Vaccine 2007;25:2228-37
   PubMed Web of Science ®Google Scholar
• Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroup A, C, D, E and F. J Virol 1998;72:7909-15
   PubMed Web of Science ®Google Scholar
• Li E, Brown SL, Stupack DG, et al. Integrin alpha (v) beta 1 is an adenovirus co-receptor. J Virol 2001;75:5405-9
   PubMed Web of Science ®Google Scholar
• Arnberg N, Kidd AH, Edlund K, et al. Initial interactions of Subgenus D adenoviruses with A549 cellular receptors: sialic acid versus αv integrins. J Virol 2000;74(16):7691-3
   PubMed Web of Science ®Google Scholar
• Dechecchi MC, Melotti P, Bonizzato A, et al. Heparan sulfate glycosaminoglycans are recptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001;75:8772-80
   PubMed Web of Science ®Google Scholar
• Fujiki N, Macer DRJ. Intractable neurological disorders, human genome research and society. Proceedings of the Third International Bioethics Seminar. Eubios Ethics Institute; 1994
   Google Scholar
• Holterman L, Vogels R, van der Vlugt R, et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 2004;8:13207-15
   Google Scholar
• Havenga M, Vogels R, Zuijdgeest K, et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol 2006;87:2135-43
   PubMed Web of Science ®Google Scholar
• Angelique AC, Grimbergen J, Smits S, et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 2006;87:2891-9
   PubMed Web of Science ®Google Scholar
• Barough DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Human Gene Ther 2005;16:149-56
   PubMed Web of Science ®Google Scholar
• Schepp-Berglind J, Luo M, Wang D, et al. Complex adenovirus-mediated expression of West Nile virus C, preM,E, and NS1 proteins induces both humoral and cellular immune responses. Clin Vaccine Immunol 2007;14:1556-6811
   Google Scholar
• Liu G, Excoffon KJ, Wilson JE, et al. Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Human Gene Ther 2000;11:21-32
   PubMed Web of Science ®Google Scholar
• Everett RS, Hodges BL, Ding EY, et al. Liver toxicities typically induced by first generation adenoviral vectors can be reduced by use of E1, E2b-deleted Ad vectors. Human Gene Ther 2003;14:1715-26
   PubMed Web of Science ®Google Scholar
• Kochanek S, Shiedner G, Volpers C. High-capacity ‘gutless’ adenoviral vectors. Curr Opin Mol Ther 2001;3:454-63
   PubMed Web of Science ®Google Scholar
• Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005;12:S18-27
   PubMed Web of Science ®Google Scholar
• Koehler DR, Martin B, Corey M, et al. Readministration of helper-dependent adenovirus to mouse lung. Gene Ther 2006;13:773-80
   PubMed Web of Science ®Google Scholar
• Holst J, Rasko JE. The use of retroviral vectors for gene transfer into hematopoietic stem cells. Methods Enzymol 2006;420:82-100
   PubMed Web of Science ®Google Scholar
• Stitz J, Buchloz CJ, Engelstadter M, et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000;273:16-20
   PubMed Web of Science ®Google Scholar
• Zhong Q, Kolls JK, Schwartenberger P. Retrovirus molecular conjugates. Cell Mol Life Sci 2002;59:2083-7
   PubMed Web of Science ®Google Scholar
• Herzog RW. Adeno-associated virus-mediated gene transfer to skeletal muscle. Methods Mol Biol 2004;256:179-94
   Google Scholar
• Kaspar BK, Vissel B, Benoechea T, et al. Adeno-associated virus effectively mediates conditioned gene modification in the brain. Proc Natl Acad Sci USA 2002;99:2320-5
   PubMed Web of Science ®Google Scholar
• Duan P, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998;72:8566-77
   Google Scholar
• Shi GX, Wang Y, Liu Y, et al. Long-term expression of a transferred gene in Epstein-Barr virus transformed human B cells. Scand J Immunol 2001;54:265-72
   PubMed Web of Science ®Google Scholar
• Kusano K, Tsutsumi Y, Dean J, et al. Long-term stable expression of human growth hormone by rAAV promotes myocardial protection post-myocardial infarction. J Mol Cell Cardiol 2007;42:390-9
   PubMed Web of Science ®Google Scholar
• Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6:1574-83
   PubMed Web of Science ®Google Scholar
• Baker AH, Kritz A, Work LM, Nicklin SA. Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol 2004;90:27-31
   PubMed Web of Science ®Google Scholar
• Warrington KH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006;119:571-603
   PubMed Web of Science ®Google Scholar
• Alisky JM, Joseph M, Hughes SM, et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 2000;11:2669-73
   PubMed Web of Science ®Google Scholar
• Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989;81:570-6
   PubMed Web of Science ®Google Scholar
• Krom YD, Gras JC, Frants RR, et al. Efficient targeting of adenoviral vectors to integrin positive vascular cells utilizing a CAR-cyclic RGD linker protein. Biochem Biophys Res Commun 2005;338:847-54
   PubMed Web of Science ®Google Scholar
• Sorscher EJ, Harris J, Alexander M, et al. Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening. Gene Ther 2006;13:781-8
   PubMed Web of Science ®Google Scholar
• Le Doux JM, Davis HE, Morgan JR, Yarmush M. Kinetics of retrovirus production and decay. Biotechnol Bioeng 1999;63:654-62
   PubMed Web of Science ®Google Scholar
• Landazuri N, Le Doux JM. Complexation of retroviruses with charged polymers enhances gene transfer by increasing the rate that viruses are delivered to cells. J Gene Med 2004;6:1304-19
   PubMed Web of Science ®Google Scholar
• Hobson DA, Pandori MW, Sano T. In situ transduction of target cells on solid surfaces by immobilized viral vectors. BMC Biotech 2003;3:1-10
   PubMedGoogle Scholar
• Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Human Gene Ther 1997;8:37-44
   PubMed Web of Science ®Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4:346-58
   PubMed Web of Science ®Google Scholar
• Meunier-Dermort C, Grimal H, Sachs LM, et al. Adenovirus enhancement of polyethylenimine-mediated transfer of regulated genes in differentiated cells. Gene Ther 1997;4:808-14
   PubMed Web of Science ®Google Scholar
• Chandler LA, Doukas J, Ganzalez AM, et al. FGF2-targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. Mol Ther 2000;2:153-60
   PubMed Web of Science ®Google Scholar
• Pascher A, Steinert AF, Palmer GD, et al. Enhanced repair of the anterior cruciate ligament by in situ gene transfer: evaluation in an in vitro model. Mol Ther 2004;10:327-36
   PubMed Web of Science ®Google Scholar
• Schek RM, Hollister SJ, Krebsbach PH. Delivery and protection of adenoviruses using biocompatible hydrogels for localized gene therapy. Mol Ther 2004;9:130-8
   PubMed Web of Science ®Google Scholar
• Gugala Z, Davis AR, Fouletier-Dilling CM, et al. Adenovirus BMP2-induced osteogenesis in combination with collagen carriers. Biomaterials 2007;28:4469-79
   PubMed Web of Science ®Google Scholar
• Hu WW, Wang Z, Hollister SJ, Krebsbach PH. Localized viral vector delivery to enhance in situ regenerative gene therapy. Gene Ther 2007;14:891-901
   PubMed Web of Science ®Google Scholar
• Levy RJ, Song C, Tallapragada S, et al. Localized adenovirus gene delivery using antiviral IgG complexation. Gene Ther 2001;8:659-67
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu JK, Krol A, et al. Systemic dissemination of viral vectors during intratumoral injection. Mol Cancer Ther 2003;2:1233-42
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu S, Li CY, Yuan F. A novel method for viral gene delivery in solid tumors. Cancer Res 2005;65:7541-5
   PubMed Web of Science ®Google Scholar
• March KL, Madison JE, Trapnell BC. Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy. Hum Gene Ther 1995;6:41-53
   PubMed Web of Science ®Google Scholar
• Feldman LJ, Pastore CJ, Aubailly N, et al. Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Gene Ther 1997;4:189-98
   PubMed Web of Science ®Google Scholar
• van Belle E, Maillard L, Rivard A, et al. Effects of poloxamer 407 on transfection time and percutaneous adenovirus-mediated gene transfer in native and stented vessels. Hum Gene Ther 1998;9:1013-24
   PubMed Web of Science ®Google Scholar
• Strppe PM, Hampton DW, Cachon-Gonzalez B, et al. Delivery of a lentiviral vector in a Pluronic F127 gel to cells of the central nervous system. Eur J Pharm Biopharm 2005;61:126-33
   PubMed Web of Science ®Google Scholar
• Hatefi A, Cappello J, Ghandehari H. Adenoviral gene delivery to solid tumors by recombinant silk-elastin-like protein polymers. Pharm Res 2007;24:773-9
   PubMed Web of Science ®Google Scholar
• Okino H, Manabe T, Tanaka M, Matsuda T. Novel therapeutic strategy for prevention of malignant tumor recurrence after surgery: Local delivery and prolonged release of adenovirus immobilized in photocured, tissue-adhesive gelatinous matrix. J Biomed Mater Res A 2003;66:643-51
   PubMedGoogle Scholar
• Kaplan JM, Pennington SE, St George JA, et al. Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. Hum Gene Ther 1998;9:1469-79
   PubMed Web of Science ®Google Scholar
• Arcasoy SM, Latoche JD, Gondor M, et al. Polycation increases the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cells in vitro. Gene Ther 1997;4:32-8
   PubMed Web of Science ®Google Scholar
• Fasbender A, Zabner J, Chillon M, et al. Complexes of adenovirus with polycationic polymers and cationic tip increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997;272:6479-89
   PubMed Web of Science ®Google Scholar
• Dodds E, Piper TA, Murphy SJ, Dickson G. Cationic Lipids and polymers are able to enhance adenoviral infection of cultured mouse myotubes. J Neurochem 1999;72:2105-12
   PubMed Web of Science ®Google Scholar
• Grubb BR, Pickles RJ, Ye H, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and human. Nature 1994;371:802-6
   PubMed Web of Science ®Google Scholar
• Le Doux JM, Morgan JR, Yarmush ML. Differential inhibition of retrovirus transduction by proteoglycans and free glycosaminoglycans. Biotechnol Prog 1999;15:397-406
   PubMed Web of Science ®Google Scholar
• Batra RK, Olsen JC, Hoganson DK, et al. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. J Biol Chem 1997;272:11736-43
   PubMed Web of Science ®Google Scholar
• Le Doux JM, Landazuri N, Yarmush ML, Morgan JR. Complexation of retrovirus with cationic and anionic polymers increases the efficiency of gene transfer. Hum Gene Ther 2001;12:1611-21
   PubMed Web of Science ®Google Scholar
• Davis HE, Rosinski M, Morgan JR, Yarmush ML. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J 2004;86:1234-42
   PubMed Web of Science ®Google Scholar
• Landazuri N, Krishma D, Gupta M, Le Doux JM. Retrovirus-polymer complexes: study of the factors affecting the dose response of transduction. Biotechnol Prog 2007;23:480-7
   PubMed Web of Science ®Google Scholar
• Totoshima K, Vogt PK. Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. Virology 1969;38:414-26
   PubMed Web of Science ®Google Scholar
• Katakura H, Harada A, Kataoka K, et al. Improvement of retroviral vectors by coating with poly(ethylene glycol)-poly(L-lysine) block copolymer (PEG-PLL). J Gene Med 2004;6:471-7
   PubMed Web of Science ®Google Scholar
• Mahato RI, Anwer K, Tagliaferri F, et al. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum Gene Ther 1998;9:2082-99
   Google Scholar
• Bragonzi A, Boletta A, Biffi A, et al. Comparison between cationic polymers and lipids in mediating systemic gene delivery to the lungs. Gene Ther 1999;6:1995-2004
   PubMed Web of Science ®Google Scholar
• Mima H, Tomoshige R, Kanamori T, et al. Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. J Gene Med 2005;7:888-97
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001;12:861-70
   PubMed Web of Science ®Google Scholar
• Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Del Rev 1997;28:5-24
   PubMed Web of Science ®Google Scholar
• Beer SJ, Hilfinger JM, Davidson BL. Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors. Adv Drug Del Rev 1997;27:59-66
   PubMed Web of Science ®Google Scholar
• Wang D, Molavi O, Lutsiak ME, et al. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination. J Pharm Sci 2007;10:217-30
   Web of Science ®Google Scholar
• Turner P, Petch A, Al-Rubeai M. Encapsulation of viral vectors for gene therapy applications. Biotechnol Prog 2007;23:423-9
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Staas JK, Tice TR, Gilley RM. Biodegradable poly(DL-lactide-co-glycolide) microspheres. Res Immunol 1992;143:557-63
   PubMedGoogle Scholar
• Eldridge JH, Staas, JK, Meulbroek JA, et al. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of neutralizing antibodies. Infect Immun 1991;59:2978-86
   PubMed Web of Science ®Google Scholar
• Matthews CB, Jenkins G, Hilfinger JM, Davidson BL. Poly-L-Lysine improves gene transfer with adenovirus formulated in PLGA microspheres. Gene Ther 1999;6:1558-64
   PubMed Web of Science ®Google Scholar
• Del Barrio GG, Hendry J, Renedo MJ. In vivo sustained release of adenoviral vectors from poly(D,L-lactic-co-glycolic) acid microparticles prepared by TROMS. J Control Rel 2004;94:229-35
   PubMed Web of Science ®Google Scholar
• Del Barrio GG, Novo FJ, Irachie JM. Loading of plasmid DNA into PLGA microparticles using toatal recirculation one-machine system (TROMS): evaluation of its integrity and controlled release properties, J Control Rel 2003;86:123-30
   PubMed Web of Science ®Google Scholar
• Periwal SB, Speaker TJ, Cebra JJ. Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates. J Virol 1997;71:2844-50
   PubMed Web of Science ®Google Scholar
• Mittal SK, Aggarwal N, Sailaja G, et al. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2008;19:252-63
   Google Scholar
• Carlesso G, Kozlov, E, Prokop A, et al. Nanoparticulate system for efficient gene transfer into refractory cell targets. Biomacromolecules 2005;6:1185-92
   PubMed Web of Science ®Google Scholar
• Kalyanasund S, Feinstein S, Nicholson JP, et al. Coacervate microspheres as carriers of recombinant adenoviruses. Cancer Gene Ther 1999;6:107-12
   PubMed Web of Science ®Google Scholar
• Lameiro MH, Malpique R, Silva AC, et al. Encapsulation of adenoviral vectors into chitosan-bile salt microparticles for mucosal vaccination. J Biotechnol 2006;126:152-62
   PubMed Web of Science ®Google Scholar
• Pandori MW, Sano T. Chemically inactivated adenoviral vectors that can efficiently transduce target cells when delivered in the form of virus-microbead conjugates. Gene Ther 2005;12:521-33
   PubMed Web of Science ®Google Scholar
• Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21
   PubMed Web of Science ®Google Scholar
• Gao GP, Alvira MR, Calcedo R, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002;99:11854-9
   PubMed Web of Science ®Google Scholar
• O'Riordan CR, Lachapell A, Delgado C, et al. Francis GE: PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999;10:1349-58
   PubMed Web of Science ®Google Scholar
• Croyle MA, Yu QC, Wilson JM. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 2000;11:1713-22
   PubMed Web of Science ®Google Scholar
• Lee GK, Maheshri N, Kaspar B, Schaffer DV. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng 2005;92:24-34
   PubMed Web of Science ®Google Scholar
• Le HT, Yu QC, Wilson JM, Croyle MA. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J Control Rel 2005;108:161-77
   PubMed Web of Science ®Google Scholar
• Kim YK, Park IK, Jiang HL, et al. Regulation of transduction efficiency by PEGylation of baculovirus vector in vitro and in vivo. J Biotechnol 2006;125:104-9
   PubMed Web of Science ®Google Scholar
• Eto Y, Gao JQ, Sekguchi F, et al. Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA). Biol Pharm Bull 2004;27:936-8
   PubMed Web of Science ®Google Scholar
• Eto Y, Gao JQ, Sekiguchi F, et al. PEGylated adenovirus vectors containing RGD petides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005;7:604-12
   PubMed Web of Science ®Google Scholar
• Lanciotti J, Song A, Doukas J, et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. J Nucl Med 2003;47:130-9
   Google Scholar
• Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005;11:66-79
   PubMed Web of Science ®Google Scholar
• Gao JQ, Eto Y, Yoshioka Y, et al. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Rel 2007;122:102-10
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, Meada H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11:812-8
   PubMed Web of Science ®Google Scholar
• Ogawara K, Rots MG, Kok RJ, et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 2004;15:433-43
   PubMed Web of Science ®Google Scholar
• Croyle MA, Chirmule N, Zhang Y, Wilson J. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on re-administration to liver. Hum Gene Ther 2002;13:1887-900
   PubMed Web of Science ®Google Scholar
• Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 2005;12:579-58
   PubMed Web of Science ®Google Scholar
• Hofherr SE, Mok H, Gushiken FC, et al. Polyethylene glycol modification of adenovirus deduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther 2007;18:837-48
   PubMed Web of Science ®Google Scholar
• Raja KS, Wand Q, Gonzalez MJ, et al. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 2003;4:472-6
   PubMed Web of Science ®Google Scholar
• Tomoko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997;94:3352-6
   PubMed Web of Science ®Google Scholar
• Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3
   PubMed Web of Science ®Google Scholar
• Nemerow GR, Stewart PL. Role of alpha (v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Rev 1999;63:725-34
   PubMed Web of Science ®Google Scholar
• Xiong Z, Cheng Z, Zhang X, et al. Imaging chemically modified adenovirus for targeting tumors expressing integrin ∞Vβ3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med 2006;47:130-9
   PubMed Web of Science ®Google Scholar
• Kreppel F, Gackowski J, Schmidt E, Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and re-targeting of adenovirus vectors. Mol Ther 2005;12:107-17
   PubMed Web of Science ®Google Scholar
• Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans 2007;35:56-60
   PubMed Web of Science ®Google Scholar
• Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000;50:61-81
   PubMed Web of Science ®Google Scholar
• Fisher KD, Stallwood Y, Green NK, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies. Gene Ther 2001;8:341-8
   PubMed Web of Science ®Google Scholar
• Parker AL, Fisher KD, Oupicky D, et al. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. J Drug Target 2005;13:39-51
   PubMed Web of Science ®Google Scholar
• Carlisle RC, Briggs SS, Hale AB, et al. Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA. Gene Ther 2006;13:1579-86
   PubMed Web of Science ®Google Scholar
• Stevenson M, Boos E, Herbert C, et al. Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells. Gene Ther 2006;13:356-68
   PubMed Web of Science ®Google Scholar
• Stevenson M, Hale AB, Hale SJ, et al. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumour-specific targeting via α6-integrins. Cancer Gene Ther 2007;14:335-45
   PubMed Web of Science ®Google Scholar
• Fisher KD, Green NK, Hale A, et al. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target 2007;15:546-51
   PubMed Web of Science ®Google Scholar
• Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007;67:429-32
   PubMed Web of Science ®Google Scholar
• Huang KS, Lai TH, Lin YC. Using a microfluidic chip and internal gelation reaction for monodisperse calcium alginate microparticles generation. Front Biosci 2007;12:3061-7
   PubMed Web of Science ®Google Scholar
• Croyle MA, Cheng, X, Wilson JM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther 2001;8:1281-90
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Grimes GJ, Potti GK, et al. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine 2006;24:5064-72
   PubMed Web of Science ®Google Scholar
• Gupta SS, Raja KS, Kaltgrad E, et al. Virus-glycopolymer conjugates by copper(I) catalysis of atom transfer radical polymerization and azide-alkyne cycloaddition. Chem Commun 2005;4315-7
   PubMed Web of Science ®Google Scholar
• Pandori MW, Sano T. Photoactivable retroviral vectors: a strategy for targeted gene delivery. Gene Ther 2000;7:1999-2006
   PubMed Web of Science ®Google Scholar
• Greenwald RB, Choe YH, McGuire C, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Del Rev 2003;55:217-50
   PubMed Web of Science ®Google Scholar
• Lee S, Ravindran S, Vellekamp G. Investigations of PEGylated recombinant adenovirus, using fluorescein-labeled polyethylene glycol. Hum Gene Ther 2007;18:286-300
   PubMed Web of Science ®Google Scholar
• Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nat Biotechnol 2004;22:3-4
   PubMed Web of Science ®Google Scholar